About Genetic Analysis AS

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development.  The unique GA-map® platform is based on a pre-targeted multiplex approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need of further bioinformatics work.

GA’s mission is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA holds 22 highly qualified employees with relevant scientific backgrounds and with competence in bioinformatics, molecular biology, and bioengineering.

We have core competence in detecting microorganisms like bacteria and viruses in stool and have the ability to develop In Vitro Diagnostic tests in all diseases where microbiota is involved. We are the first company in the world to develop, document, clinically validate and commercialize a CE-marked In Vitro Diagnostic test (GA-map® Dysbiosis Test Lx) for diagnosis and characterizing of dysbiosis in IBS and IBD patients. Our test has been used in 50 clinical trials and reported in 25+ scientific publications. In 2020 we launched the first CE-marked GA-map® COVID-19 fecal test. A Qualitative Real Time PCR test for the detection of the 2019 novel coronavirus (SARS-CoV-2) RNA in stool samples.